| ID | 1113 |
| Name of the vaccine | BAT |
| Microbe | Bacteria |
| Disease name | Botulism |
| Name of bacteria | Clostridium botulinum |
| Type of vaccine | Toxoid |
| Nucleic acid content | DNA |
| Age | NA |
| Description of the vaccine | Botulism antitoxin heptavalent (A, B, C, D, E, F, G) - (Equine). |
| Name of the manufacturer | Cangene Corporation, a subsidiary of Emergent BioSolutions Inc. |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2013 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive anaerobic bacterium. |
| Efficacy | In guinea pig, 100% for neurotoxin serotype A, B, E and F, 97% in C and D.
In non-human primate, 47% survival rate. |
| Vaccine formulation | Sterile suspension |
| Dosage | Adults: One vial
Pediatric (1 to 17 years): 20-100% of adult dose
Infants: 10% of adult dose regardless of body weight |
| Mechanism of action | Passive immunization with equine polyclonal antibody fragments. |
| Route of administration | Intravenous |
| Indications | Treatment of symptomatic botulism exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Headache, nausea, pruritus, urticaria, pyrexia, rash, chills and edema. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/85514/download |
| Other name | NA |
| Additional Links | NA
|